0001209191-23-005234.txt : 20230127
0001209191-23-005234.hdr.sgml : 20230127
20230127161818
ACCESSION NUMBER: 0001209191-23-005234
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230125
FILED AS OF DATE: 20230127
DATE AS OF CHANGE: 20230127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lee Yuchun
CENTRAL INDEX KEY: 0001334365
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 23563145
MAIL ADDRESS:
STREET 1: 170 TRACER LA.
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-25
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001334365
Lee Yuchun
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
0
0
0
Common Stock
2023-01-25
4
M
0
4000
72.14
A
5875
D
Common Stock
2023-01-25
4
S
0
800
312.80
D
5075
D
Common Stock
2023-01-25
4
S
0
2621
314.10
D
2454
D
Common Stock
2023-01-25
4
S
0
579
314.95
D
1875
D
Common Stock
2023-01-26
4
M
0
4000
72.14
A
5875
D
Common Stock
2023-01-26
4
S
0
302
315.42
D
5573
D
Common Stock
2023-01-26
4
S
0
1140
316.82
D
4433
D
Common Stock
2023-01-26
4
S
0
1000
317.95
D
3433
D
Common Stock
2023-01-26
4
S
0
478
319.25
D
2955
D
Common Stock
2023-01-26
4
S
0
400
320.25
D
2555
D
Common Stock
2023-01-26
4
S
0
680
320.94
D
1875
D
Stock Option (Right to Buy)
72.14
2023-01-25
4
M
0
4000
0.00
D
2024-05-31
Common Stock
4000
5429
D
Stock Option (Right to Buy)
72.14
2023-01-26
4
M
0
4000
0.00
D
2024-05-31
Common Stock
4000
1429
D
Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $312.80 (range $312.41 to $313.06).
Open market sales reported on this line occurred at a weighted average price of $314.10 (range $313.53 to $314.50).
Open market sales reported on this line occurred at a weighted average price of $314.95 (range $314.58 to $315.14).
Open market sales reported on this line occurred at a weighted average price of $315.42 (range $315.23 to $315.66).
Open market sales reported on this line occurred at a weighted average price of $316.82 (range $316.23 to $317.16).
Open market sales reported on this line occurred at a weighted average price of $317.95 (range $317.43 to $318.35).
Open market sales reported on this line occurred at a weighted average price of $319.25 (range $318.79 to $319.56).
Open market sales reported on this line occurred at a weighted average price of $320.25 (range $319.80 to $320.77).
Open market sales reported on this line occurred at a weighted average price of $320.94 (range $320.89 to $320.99).
Fully vested.
/s/ Christiana Stevenson, Attorney-in-Fact
2023-01-27